Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Cilnidipine is a novel, effective, and safe CCB that inhibits L-type and N-type calcium channels, regulating cardiac function. It is recommended for combination therapy in diabetic hypertensive patients to reduce cardiovascular and renal risks. ARBs, like telmisartan and losartan, are effective in reducing cardiovascular risk factors and renal complications. Cilnidipine's reno-protective and cardioprotective benefits make it the preferred choice for hypertensive patients with diabetes. Listen to the expert to know more on the Cilnidipine + ARB for Diabetic Hypertensives .

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals.

High blood pressure (HBP) is a symptomless "silent killer" that can lead to serious health problems. To reduce high blood pressure, lifestyle changes can be made such as eating healthy, exercising, quitting smoking, cutting down on alcohol, getting a good night's sleep, reducing stress, and monitoring blood pressure at home. These changes can help reduce the risk of heart disease, stroke, kidney disease, and more.

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Angiotensin receptor blockers (ARBs) are widely used antihypertensive drugs that help reduce the cardiovascular and cerebrovascular risks and renal complications in patients with hypertension. Telmisartan has been shown to improve renal endothelial function, prevent progression from microalbuminuria to macroalbuminuria, slow the decline in glomerular filtration rate, and reduce proteinuria in overt nephropathy. Combination of an ARB and an ACE inhibitor is not recommended as it is associated with an excess of adverse renal events. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. Listen to the expert to know more on the ARB in Diabetes

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

As per WHO, nearly 63% of total deaths in India are due to non-communicable diseases, of which 27% are attributed to CVD which affects 45% of people in the 40-69 age group. Raised blood pressure is among the most important risk factors for CVDs which remains poorly controlled due to low awareness about hypertension, lack of appropriate care through primary care, and poor follow-up of the patients. In India, the prevalence has also gone up over 30 years to 38% in men and 32% in women.  Despite that, nearly 51% of the men and 41% of women with hypertension were unaware of the condition. Listen to the expert to know more on the latest updates in Hypertension.